Search company, investor...
Immunocore company logo


Founded Year




Total Raised


Date of IPO


About Immunocore

Immunocore is a T cell receptor biotechnology company, focused on delivering biological therapies that have the potential to transforms the lives of people with serious diseases.

Headquarters Location

92 Park Drive Milton Park

Abingdon, England, OX14 4RY,

United Kingdom

+44 (0)1235 438600

Missing: Immunocore's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Immunocore's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Immunocore

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Immunocore is included in 4 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,898 items

Immunocore Patents

Immunocore has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Immune system, Immunology, Clusters of differentiation, T cells, Human cells


Application Date


Grant Date



Related Topics

Immune system, Immunology, Clusters of differentiation, T cells, Human cells



Latest Immunocore News featured highlights include Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services...

Nov 22, 2022

For Immediate Release Chicago, IL November 22, 2022 Stocks in this weeks article are Immunocore Holdings plc IMCR, Old Second Bancorp Inc. OSBC, EDAP TMS S.A. EDAP, Barrett Business Services Inc. BBSI and MainStreet Bancshares Inc. MNSB. 5 Stocks with Recent Price Gains to Maximize Your Returns Wall Street closed a fabulous October after a highly disappointing September. The rally is continuing this month. We are not out of the woods as inflation remains elevated. However, recently released several data have clearly shown that inflation is dwindling albeit at a slow pace. AD AD On Nov 10, the Department of Labor reported that the consumer price index (CPI) in October rose 0.4% month over month and 7.7% year over year. The consensus estimate was for a month-over-month rise of 0.5% and a year-over-year gain of 7.9% Core CPI (excluding volatile food and energy items) increased 0.3% month over month and 6.3% year over year. The consensus estimate was of a rise of 0.5% month over month and 6.5% year over year.

Immunocore Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Immunocore Rank

Immunocore Frequently Asked Questions (FAQ)

  • When was Immunocore founded?

    Immunocore was founded in 2008.

  • Where is Immunocore's headquarters?

    Immunocore's headquarters is located at 92 Park Drive, Abingdon.

  • What is Immunocore's latest funding round?

    Immunocore's latest funding round is IPO.

  • How much did Immunocore raise?

    Immunocore raised a total of $743.66M.

  • Who are the investors of Immunocore?

    Investors of Immunocore include Oxford Finance, BlackRock, RTW Investments, Bill & Melinda Gates Foundation, Eli Lilly and Company and 11 more.

  • Who are Immunocore's competitors?

    Competitors of Immunocore include iOnctura.

Compare Immunocore to Competitors


iOnctura is a clinical-stage biopharmaceutical company focused on delivering cancer treatments to patients with unmet medical needs. It is uncovering the key to unlock difficult-to-treat tumors burdened by stroma and immune mediated resistance. The company does this by interrogating new mechanisms that disrupt the dynamic interplay at the heart of the tumor-stroma-immune interface. iOnctura was founded in 2017 and is based in Geneva, Switzerland.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.